Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
Rituximab
(section)
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
==Clinical trial groups== ===United Kingdom === The British patient charity, [[Invest in ME]], supported a Rituximab study in the UK, led by [[Jonathan Edwards]],<ref>[http://www.ukrituximabtrial.org/ UK Rituximab Trial]</ref> but in February 2018, deemed "that a UK trial is not possible or advisable following the negative Norwegian trial results."<ref>{{Cite web|url=http://www.investinme.org/IIMER-Newslet-1802-01.shtml | title = Statement on Rituximab Trial and Research | last = | first = | authorlink = | date = | website=[[Invest in ME Research]]|archive-url=|archive-date=|url-status=|access-date=2021-11-21}}</ref> [[Jonathan Edwards]] became interested in the use of Rituximab on ME/CFS patients after attending the [[Invest in ME International ME Conference]] in May 2013.<ref>[http://www.ukrituximabtrial.org/Rituximab%20news-July13%2001.htm UK Rituximab Trial - Statements By Professor Jonathan Edwards and Invest in ME | July 2013]</ref> ===Norway=== The Norwegian team published more trials, but a 2019 phase III trial of rituximab showed no benefit: *2019, B-Lymphocyte depletion in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a randomized, double-blind, placebo-controlled trial<ref name="phase3-2019" /> ::This phase 3 trial of rituximab showed no benefits. *[https://clinicaltrials.gov/ct2/show/NCT02229942?term=rituximab+cfs&rank=1 NCT02229942 - B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study, (RituxME)]. [https://www.dagensmedisin.no/artikler/2017/11/24/me-studie-med-negative-resultater/ Preliminary results were negative] *[https://clinicaltrials.gov/ct2/show/NCT01156922?term=rituximab+cfs&rank=2 NCT01156922 - B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome] *[http://www.helse-bergen.no/en/OmOss/Avdelinger/kreft/forsking-fagutvikling/Sider/RituxME.aspx RituxME - B-lymphocyte depletion using the anti-CD20 antibody rituximab (Mabthera®) in Myalgic Encephalopathy/Chronic Fatigue Syndrome ("RituxME")] {{See also|RituxME}} ===United States === In late fall 2015, Dr. [[Francis Collins]] announced that the [[NIH]] was considering the possibility of sponsoring a clinical trial for Rituximab, as well as [[Ampligen]] and other treatments.<ref>[http://www.meaction.net/2015/12/21/nih-considering-ampligen-and-rituximab-trials/ ME Action - NIH Considering Ampligen and Rituximab Trials | 21 December 2015]</ref> A [[cyclophosphamide]] trial by the same team showed benefits, and studies are continuing on it. ::[https://clinicaltrials.gov/ct2/show/NCT02444091 Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS) (CycloME)] {{see also|Cyclophosphamide}}
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs